Tyrosine kinase inhibitors and anti-angiogenic therapies in kidney cancer

Current Treatment Options in Oncology

Volumn 8, Issue 3, 2007, Pages 211-226

  Haas, Naomi B ^a   Uzzo, Robert G ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 869; ALPHA INTERFERON; ALPHA2A INTERFERON; ANTILIPEMIC AGENT; AXITINIB; B RAF KINASE; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; CEDIRANIB; EVEROLIMUS; FLUOROURACIL; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN; MONOCLONAL ANTIBODY G250; PAZOPANIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR B; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT ALPHA2B INTERFERON; SORAFENIB; STEM CELL FACTOR RECEPTOR; STEROID; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VON HIPPEL LINDAU PROTEIN;

ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COUGHING; CYTOREDUCTIVE SURGERY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INHIBITION; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEVER; GENE DELETION; GENE EXPRESSION; GENE TARGETING; HAND FOOT SYNDROME; HEART EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HETEROZYGOSITY LOSS; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOPHOSPHATASIA; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; KIDNEY CARCINOMA; LAPAROSCOPIC SURGERY; LYMPH NODE METASTASIS; LYMPHOCYTOPENIA; META ANALYSIS; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NAUSEA; NEPHRECTOMY; NEUTROPENIA; ONCOGENE; OVERALL SURVIVAL; PATHOGENESIS; PNEUMONIA; PROGNOSIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN TARGETING; QT INTERVAL; RASH; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TUMOR SUPPRESSOR GENE;

ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 38149111085     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-007-0031-3     Document Type: Article

References (68)

1. Jemal A, Murray T, Ward E, et al.: Cancer statistics. CA Cancer J Clin 2005, 55:10-30
2. Cohen HT, McGovern FJ: Renal-cell carcinoma. N Engl J Med 2005, 353:2477-2490
3. Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DYT, Uzzo RG: The natural history of observed enhancing renal masses: Meta-analysis and review of the world literature. J Urol 2006, 175:425-431
4. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T: Immunotherapy for advanced renal cell carcinoma. Cochrane Database Syst Rev 2005, 25(1):CD001425
5. Frank I, Blute ML, Leibovich BC, et al.: Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. J Urol 2005, 173:1889-1892
6. Moinzadeh A, Gill IS, Finelli A, Kaouk J, Desai M: Laparoscopic partial nephrectomy: 3-year followup. J Urol 2006, 175:459-462
7. Gill IS, RemerOEM, Hasan WA, et al.: Renal cryoablation: outcome at 3 years. J Urol 2005, 173:1903-1907
8. Yagoda A, Petrylak D, Thompson S: Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 1993, 20(2):303-321
9. Flanigan RC, Salmon SE, Blumenstein BA, et al.: Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal cell cancer. N Engl J Med 2001, 345:1655-1659
10. Enquist E, Zambrano N, Zbar B, et al: Molecular genetics of renal cell carcinoma. In Bukowski RM, Novick AC (eds). Renal Cell Carcinoma: Molecular biology, Immunology, and Clinical Management. Totowa, N.J.: Humana Press Inc, 2000;pp 79-93
11. Knudson AG Jr.: Genetics of human cancer. Annu Rev Genet 1986, 20:231-251
12. Uzzo RG, Novick AC: VoC Hippel Lindau syndrome: clinical and molecular considerations for the urologist. AUA Update Ser 1999, 18:137-144
13. Lubensky IA, Schmidt L, Zhuang Z, et al.: Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol 1999, 155:517-526
14. Uzzo RG, Cairns P, Al-Saleem T, Hudes G, Haas N, Greenberg RE, Kolenko V: The basic biology and immunobiology of renal cell carcinoma: considerations for the clinician. Urol Clin North Am 2003, 30:423-436
15. Baylin SB, Herman JG, Graff JR, et al.: Alterations in DNA methylation: a fundamental aspects of neoplasia. Adv Cancer Res 1998, 72:141-196
16. Gnarra JR, Lerman MI, Zbar B, et al.: Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis. Semin Oncol 1995, 22:3-8
17. Linehan WM, Lerman MI, Zbar B: Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA 1995, 273:564-570
18. Foster K, Prowse A, van den Berg A, et al.: Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genet 1994, 3:2169-2173
19. Hatano N, Nishikawa NS, McElgunn C, et al.: A comprehensive analysis of loss of heterozygosity caused by hemizygous deletions in renal cell carcinoma using a subtraction library. Mol Carcinog 2001, 31:161-170
20. Schmidt L, Duh FM, Chen F, et al.: Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997, 16:68-73
21. Speicher MR, Schoell B, du Manoir S, et al.: Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization. Am J Pathol 1994, 145:356-364
22. Stadler WM: Targeted agents for the treatment of advanced renal cell carcinoma. Cancer 2005, 104(11):2323-2333
23. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003, 9(1):327-337
24. O'Farrel AM, et al.: SU 11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003, 101:3597
25. Fiedler W, et al.: A phase I study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia or not amenable to conventional therapy for the disease. Blood 2004, 5:1846
26. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD: Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006, 295(21):2516-2524
27. Motzer RJ, et al.: SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second line therapy for patients with metastatic renal cell carcinoma: Results of a phase II study. Proc Am Soc Clin Oncol 2004, Abs#4500
28. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet. 2006, 368(9544):1329-1338
29. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Kim ST, Baum CM, Figlin RA: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356(2):115-124
30. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Bollag G, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Trail PA: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64(19):7099-7109
31. Escudier B, Eisen T. Stadler W, et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356(2):125-134
32. Szczylik C, Demkow T, Staehler M, et al.: Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I 2007, 25(18S): 5025
33. Amato RJ, Harris P, Dalton M, et al.: A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC). J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I 2007, 25(18S): 5026
34. Rini B, Rixe O, Bukowski R, et al.: AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). J Clin Oncol, 2005 ASCO Annual Meeting Proceedings 2005, 23(16S) Part I of II (June 1 Supplement): 4509
35. Hurwitz H, Dowlati A, Savage S, et al.: Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings 2005, 23(16S) Part I of II (June 1 Supplement): 3012
36. Albert DH, Tapang P, Magoc TJ, et al.: Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther 2006, 5(4):995-1006
37. Van Cruijsen H, Voest EE, Van Herpen CM, et al.: Phase I evaluation of AZD2171, a highly potent, selective VEGFR signaling inhibitor, in combination with gefitinib, in patients with advanced tumors. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I 2006, 24(18S): 3017
38. Albers MW, Williams RT, Brown EJ, Tanaka A, Hall FL, Schreiber SL: FKBP-rapamycin inhibits a cyclin-dependent kinase activity and a cyclin D1-Cdk association in early G 1 of an osteosarcoma cell line. J Biol Chem 1993, 268:22825-22829
39. Hidalgo M, Rowinsky EK: The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 2000, 19(56):6680-6686 Oncogene 2000, 19(56):6680-6686
40. Brown EJ, Albers MW, Shin TB, Ocjlawa K, Keith CT, Lane WS, Schreiber SLA: Mammalian protein targeted by G1-arresting rapamycin receptor complex. Nature 1994, 369:756-758
41. Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, Zupi G, Milella M: Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 2006, 66(11):5549-5554
42. Hudes G, Carducci M, Tomczak P, et al.: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356(22):2271-2281
43. Figlin RA, Seligson D, Wu H, et al.: Characterization of the mTOR pathway in renal cell carcinoma and its use in predicting patient selection for agents targeting this pathway. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings 2005, 23(16S) Part I of II (June 1 Supplement): 4539
44. Amato RJ, Misellati A, Khan M, Chiang S: A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I 2006, 24(18S): 4530
45. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349(5):427-434.
46. Rini B, Halabi S, Taylor J, eA al.: Cancer and leukemia group B 90206: a randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res 2004, 10(8):2584-2586.
47. Escudier B, Koralewski P, Pluzanska A, et al.: A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/ interferon-α2a vs placebo/interferon- α2a as first-line therapy in metastatic renal cell carcinoma. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I, 2007, 25(18S): 3
48. Veronese ML, Mosenkis A, Flaherty KT, et al.: Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006, 24(9):1363-1369
49. Govindarajan R, Adusumilli J, Baxter DL, et al.: Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. J Clin Oncol 2006, 24(28):e48
50. Ewer MS, Lippman SM: Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 2005, 23(13):2900-2922
51. Robert C, Soria JC, Spatz A, et al.: Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005, 6(7):491-500
52. Lokich JJ, Moore C: Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 1984, 101(6):798-799
53. Robert C, Faivre S, RaymonA E, et al.: Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors? Ann Intern Med 2005, 143(4):313-314
54. Routhouska S, Gilliam AC, Mirmirani P: Hair depigmentation during chemotherapy with a class III/V receptor tyrosine kinase inhibitor. Arch Dermatol 2006, 142(11): 1477-1479
55. Desai J, Yassa L, Marqusee E, et al.: Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006, 145(9):660-664
56. Sandler A, Gray R, Perry MC, et al.: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355(24):2542-2550
57. Investigator Safety Report for CCI-779, Investigator's Brochure April, 2005
58. Duran I, Sin LL, Oza Am, et al.: Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 2006, 42(12):1875-1880
59. Galanis E, Buckner JC, Maurer MJ, et al.: Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group Study. J Clin Oncol 2005, 23(23):5294-5304
60. Chang SM, Wen P, Cloughesy T, et al.: Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 2005, 23(4):357-361
61. Huffman TA, Mothe-Satney I, Lawrence JC Jr.: Insulin-stimulated phosphorylation of lipin mediated by the mammalian target of rapamycin. Proc Natl Acad Sci USA 2002, 99(2):1047-1052
62. Kunkle DA, Haas NB, Uzzo RG: Adjuvant strategies for high risk renal cell carcinoma patients. Curr Urol Rep 2007, 8(1):19-30
63. Jocham D, Richter A, Hoffman L, et al.: Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomized controlled trial. Lancet 2004, 363:594-599
64. Uzzo RG, Novick AC: The role of nephrectomy and metastasectomy in advanced renal cell carcinoma. In: Bukowski RM, Novick AC (eds) Renal Cell Carcinoma: Molecular Biology, Immunology, and Clinical Management. Totowa, NJ: The Humana Press, (2000); pp 215-228
65. Mickisch GA, van Poppel H, de Prijck L, Sylvester R, European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001, 358(9286):966-970
66. Halbert RJ, Figlin RA, Atkin MB, Bernal M, Hutson TE, Uzzo RG, Bukowski RM, Khan KD, Wood CG, Dubois R: Treatments for patients with metastatic renal cell cancer: A rand appropriateness panel. Cancer 2006, 107(10):2375-2383
67. Scappaticci FA, Fehrenbacher L, Cartwright T, et al.: Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005, 91(3):173-180
68. D'Angelica M, Kornprat P, Gonen M, et al.: Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: A matched case-control study. Ann Surg Oncol 2007, 14: 759-765